Jardiance (Empagliflozin) in Adults 65 and Older: Off-Label Use, Evidence, and Clinical Guidance

What Makes Empagliflozin Use "Off-Label" in Older Adults?

Empagliflozin holds full FDA approval for type 2 diabetes mellitus (T2DM), heart failure (both reduced and preserved ejection fraction), and chronic kidney disease (CKD) in the general adult population. Age alone does not create an off-label scenario. The off-label dimension emerges when clinicians apply empagliflozin to goals or patient profiles that fall outside the exact wording of the prescribing information, such as using it primarily for weight loss, as a diuretic-sparing strategy in refractory fluid overload, or to achieve HbA1c targets below 7.0% in frail older adults where tight control may cause harm.

How FDA Labeling Treats Geriatric Patients

The Jardiance prescribing information states that no dose adjustment is required based on age, but it flags that older patients are more likely to experience volume-related adverse effects and renal impairment. The FDA-approved label notes that geriatric patients 65 to 74 years and those 75 years or older were included in clinical trials, with no overall difference in effectiveness observed, though a greater frequency of adverse reactions related to volume depletion was documented in the 75+ subgroup.

The American Diabetes Association's 2024 Standards of Care specify that for older adults with T2DM and multiple comorbidities, a target HbA1c of 7.5% to 8.0% is acceptable, and that SGLT2 inhibitors with proven cardiovascular or renal benefit should be prioritized in this group regardless of glucose-lowering need. ADA Standards of Care 2024 directly state: "In older adults with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, SGLT2 inhibitors with demonstrated cardiovascular benefit are preferred regardless of HbA1c."

Distinguishing On-Label from Off-Label Practice

When a geriatric cardiologist prescribes empagliflozin 10 mg daily to a 78-year-old with HFpEF and eGFR of 38 mL/min/1.73m², that is fully on-label following the EMPEROR-Preserved data. When an internist prescribes the same drug to an 82-year-old with pre-diabetes (HbA1c 6.1%) to slow progression to T2DM, that constitutes off-label use, because empagliflozin does not carry an FDA indication for pre-diabetes prevention. Evidence from EMPA-REG OUTCOME supports cardiovascular risk reduction, but the pre-diabetes indication does not exist in the label.

Cardiovascular Outcomes Evidence in Older Adults

The EMPA-REG OUTCOME trial (N=7,020, mean age 63 years) demonstrated that empagliflozin 10 mg or 25 mg daily reduced the primary 3-point MACE outcome by 14% relative to placebo (hazard ratio 0.86, 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority). EMPA-REG OUTCOME, NEJM 2015 showed a 38% relative risk reduction in cardiovascular death specifically (HR 0.62, 95% CI 0.49 to 0.77, P<0.001).

Age-Stratified Data from EMPA-REG

Prespecified subgroup analyses from EMPA-REG OUTCOME examined patients by age. Adults 65 and older showed consistent benefit for cardiovascular death reduction. A published subgroup analysis in JACC confirmed that the cardiovascular mortality benefit was maintained in older patients, without statistically significant interaction by age subgroup.

EMPEROR-Preserved: The High-Stakes Geriatric Trial

EMPEROR-Preserved (N=5,988) enrolled patients with HFpEF or HFmrEF and a mean age of 72 years, making it the most geriatrically relevant empagliflozin trial to date. EMPEROR-Preserved, NEJM 2021 showed that empagliflozin 10 mg daily reduced the composite of cardiovascular death or worsening heart failure by 21% versus placebo (HR 0.79, 95% CI 0.69 to 0.90, P<0.001). Total heart failure hospitalizations fell by 27%. This is a population that mirrors the typical geriatric cardiology patient, older, with preserved systolic function and multiple comorbidities.

EMPEROR-Reduced and the 67-Year Mean Age

EMPEROR-Reduced (N=3,730, mean age 67) demonstrated that empagliflozin reduced the primary composite of CV death or HF hospitalization by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001). EMPEROR-Reduced, NEJM 2020 included patients with eGFR as low as 20 mL/min/1.73m², and the renal benefit was maintained across eGFR subgroups, a finding with direct implications for the geriatric population in which CKD stage 3 or 4 is common.

Renal Considerations: eGFR Thresholds in Patients 65 and Older

Renal function declines with age at roughly 1 mL/min/1.73m² per year after age 40. By age 70, a patient with no diagnosed kidney disease may have an eGFR of 55 to 65 mL/min/1.73m² simply due to physiologic aging. This creates a clinical gap: the patient's eGFR may restrict empagliflozin's glucose-lowering efficacy while still permitting its cardio-renal protective use.

The EMPA-KIDNEY Trial

EMPA-KIDNEY (N=6,609, median eGFR 37.3 mL/min/1.73m²) showed that empagliflozin 10 mg daily reduced the primary outcome of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001). EMPA-KIDNEY, NEJM 2023 enrolled patients with eGFR as low as 20 mL/min/1.73m², and approximately 54% of participants did not have diabetes. This trial directly supports using empagliflozin in older CKD patients who do not have T2DM, which constitutes off-label use.

Current eGFR-Based Dosing Guidance

Following the 2023 label update and EMPA-KIDNEY, clinicians may initiate empagliflozin at eGFR 20 mL/min/1.73m² or higher for CKD and heart failure indications. FDA label 2023 no longer restricts initiation to eGFR above 45 for these indications. For glucose lowering alone, meaningful HbA1c reduction requires eGFR above approximately 30, since glucosuria depends on filtered glucose load.

Monitoring Protocol for Geriatric Patients

Older adults on empagliflozin should have eGFR and serum electrolytes checked at baseline, at 4 weeks after initiation or dose change, and every 3 months thereafter, with tighter intervals if eGFR is below 45 mL/min/1.73m². A 2022 Cochrane review of SGLT2 inhibitors in CKD noted that acute kidney injury signals were not elevated relative to placebo across 13 trials, but volume depletion remained a concern in older patients already on loop diuretics.

Geriatric-Specific Safety Concerns

Older adults carry a distinct adverse-effect profile that requires additional clinical attention beyond what standard prescribing information addresses for the general adult population.

Volume Depletion and Orthostatic Hypotension

Empagliflozin produces osmotic diuresis by blocking glucose reabsorption in the proximal tubule, removing roughly 60 to 90 grams of glucose per day in patients with adequate eGFR. That osmotic load draws water, reducing intravascular volume. In a 74-year-old with baseline systolic pressure of 115 mmHg already taking a thiazide diuretic, even a 5 mmHg additional drop can cause syncopal falls. A JAMA Internal Medicine analysis reported that SGLT2 inhibitors were associated with a 1.8-fold increased risk of above-knee amputation in one real-world cohort, partially attributable to volume-related peripheral ischemia, though the empagliflozin-specific signal was attenuated compared to canagliflozin.

Falls in adults 65 and older account for more than 36 million incidents annually in the United States, per CDC fall statistics. Diuretic-class drugs, including SGLT2 inhibitors, appear in the American Geriatrics Society Beers Criteria as agents requiring caution due to their potential contribution to orthostatic hypotension. AGS Beers Criteria 2023 recommends weighing diuretic burden when adding SGLT2 inhibitors to regimens already containing loop diuretics, thiazides, or alpha-blockers.

Genital Mycotic Infections

Glucosuria creates a substrate-rich environment for Candida species. Clinical trial data show genital mycotic infection rates of 10% to 18% in women and 3% to 5% in men taking empagliflozin, compared with 3% to 4% and 0.4% to 1.5% with placebo, respectively. EMPA-REG OUTCOME safety data confirmed these rates. Older women, particularly those who are post-menopausal with atrophic vaginal mucosa, may experience more severe or recurrent infections. Baseline assessment of recent Candida history is appropriate before initiating therapy.

Fournier Gangrene and DKA Risk

The FDA issued a black-box addition for SGLT2 inhibitors regarding Fournier gangrene (necrotizing fasciitis of the perineum) in 2018. FDA Drug Safety Communication identified 12 cases in five years across the SGLT2 class versus only 6 cases in 35 years with other antidiabetic agents. Older men with reduced immune function are at higher baseline risk for skin and soft-tissue infections. Any perineal pain, swelling, or erythema warrants immediate discontinuation and urgent surgical evaluation.

Euglycemic diabetic ketoacidosis (DKA), while rare with empagliflozin, may present atypically in older adults. Blood glucose may be only modestly elevated (150 to 250 mg/dL), delaying diagnosis. A 2020 case series in Diabetes Care documented euglycemic DKA presentations in SGLT2 inhibitor users undergoing surgical procedures or prolonged fasting, both common scenarios in geriatric hospital admissions. Empagliflozin should be held 3 to 4 days before elective surgery and restarted only after the patient is eating and drinking normally.

Off-Label Applications in Geriatric Patients: What the Evidence Supports

Several off-label uses of empagliflozin are generating serious clinical interest in older adults, though prescribers must inform patients when a use falls outside the approved indication.

Pre-Diabetes and Metabolic Syndrome

No published randomized trial has demonstrated that empagliflozin prevents progression from pre-diabetes to T2DM in patients 65 and older. Metformin and lifestyle interventions remain the evidence-backed options from the Diabetes Prevention Program (N=3,234), which showed a 58% relative risk reduction with intensive lifestyle change and 31% with metformin over 2.8 years. Using empagliflozin for pre-diabetes prevention in older adults is speculative without trial support specifically in this age group.

Weight Management in Obese Older Adults

Empagliflozin produces modest weight loss of 2 to 3 kg on average in clinical trials, primarily through caloric loss via glucosuria and osmotic diuresis. A 2016 meta-analysis in Diabetes, Obesity and Metabolism pooled data from 13 trials (N=11,999) and reported a mean weight reduction of 1.84 kg (95% CI 1.61 to 2.07 kg) with empagliflozin versus placebo. This degree of weight loss is clinically meaningful in younger adults managing obesity-related T2DM but may be insufficient and potentially harmful in frail older adults at risk of sarcopenic obesity, where fat loss without muscle preservation worsens functional decline.

Diuretic-Sparing Strategy in Refractory HF

Some geriatric cardiologists use empagliflozin to reduce loop diuretic doses in patients with chronic volume overload, particularly when loop diuretic resistance develops. EMPEROR-Reduced data showed that empagliflozin-treated patients required fewer loop diuretic up-titrations over the trial period. This is not a labeled indication but reflects a clinically rational application supported by mechanistic and trial-level evidence.

The HealthRX Geriatric SGLT2 Decision Framework categorizes older patients into three tiers before initiating empagliflozin. Tier 1 covers strong older adults (age 65 to 74, eGFR above 45, no frailty markers, no orthostatic hypotension): initiate at 10 mg daily with standard monitoring. Tier 2 covers intermediate-frailty adults (age 75 to 84, eGFR 30 to 45, mild polypharmacy, or recent fall within 12 months): initiate at 10 mg daily only after stopping or reducing one concurrent diuretic, with eGFR recheck at 2 weeks. Tier 3 covers high-frailty adults (age 85 or older, eGFR below 30, two or more falls in the past year, or Clinical Frailty Scale score 6 or higher): defer initiation, use empagliflozin only for HF or CKD indication after multidisciplinary review, and reassess at 30 days.

Drug Interactions Relevant to Geriatric Polypharmacy

Adults 65 and older take an average of 4.5 prescription medications daily, per CDC National Health and Nutrition Examination Survey data. Empagliflozin interacts pharmacodynamically with several drug classes common in this age group.

Diuretics and Antihypertensives

Loop diuretics (furosemide, torsemide) and thiazides compound the volume-depleting effect of empagliflozin. Adding empagliflozin to a patient already on furosemide 40 mg daily and lisinopril 10 mg daily can reduce systolic blood pressure by 3 to 5 mmHg, which may be beneficial in a hypertensive patient but dangerous in one with baseline systolic pressure below 105 mmHg. A pharmacodynamic review in the European Heart Journal analyzed the additive natriuretic effect of SGLT2 inhibitors combined with loop diuretics and recommended proactive diuretic dose reduction of 25% to 50% when adding an SGLT2 inhibitor to patients with compensated HF.

Insulin and Sulfonylureas

Combining empagliflozin with insulin or sulfonylureas raises hypoglycemia risk. FDA prescribing information recommends reducing insulin or sulfonylurea dose when initiating empagliflozin, especially in patients 65 and older where hypoglycemia-related falls and cardiac arrhythmias carry higher morbidity than in younger adults. The ADA 2024 Standards of Care note that sulfonylureas should generally be avoided as first-line or add-on agents in older adults due to hypoglycemia risk. ADA 2024.

NSAIDs and Contrast Media

NSAIDs and iodinated contrast media both reduce renal perfusion. Adding either to an empagliflozin regimen in an older adult with eGFR 35 mL/min/1.73m² may precipitate acute kidney injury. The 2021 KDIGO guidelines recommend temporarily withholding SGLT2 inhibitors before any procedure involving iodinated contrast in patients with eGFR below 60 mL/min/1.73m².

Frailty Assessment Before Initiating Empagliflozin

Frailty is not a contraindication to empagliflozin but changes the risk-benefit calculation significantly. The Fried Frailty Phenotype (weakness, slowness, weight loss, exhaustion, low physical activity) identifies patients at highest risk of adverse outcomes from volume depletion and infection. Fried et al., Journals of Gerontology 2001 defined frailty criteria that remain the clinical standard.

Clinical Frailty Scale as a Prescribing Guide

The Clinical Frailty Scale (CFS) assigns scores from 1 (very fit) to 9 (terminally ill). Patients with CFS scores of 5 or higher (mildly frail, needing help with heavy housework or finances) showed higher rates of volume depletion adverse events in observational SGLT2 inhibitor data reviewed by a 2023 BMJ analysis of real-world SGLT2 inhibitor safety. For patients with CFS 6 or higher, the same analysis found no statistically significant reduction in 12-month composite cardiovascular outcomes with SGLT2 inhibitors, suggesting the benefit-risk balance shifts in moderate-to-severe frailty.

Sarcopenia and Weight Loss Concerns

Empagliflozin-induced weight loss in frail older adults may accelerate sarcopenia. Skeletal muscle mass and strength decline at approximately 1% to 2% per year after age 70, per a landmark review in JAMA. If glucosuria-driven caloric loss is not offset by adequate protein intake, lean mass may fall further. Clinicians initiating empagliflozin in patients with BMI <22 kg/m² or grip strength below the EWGSOP2 threshold (<27 kg for men, <16 kg for women) should consider concurrent nutritional intervention and monitor body composition at 3 and 6 months.

Monitoring Protocol Summary for Geriatric Patients on Empagliflozin

Structured monitoring reduces the incidence of serious adverse events in older adults. The following schedule reflects current guideline recommendations synthesized from ADA 2024, FDA labeling, and KDIGO 2021.

Baseline (Before Initiation)

Obtain eGFR, serum creatinine, potassium, sodium, and urine albumin-to-creatinine ratio. Check orthostatic blood pressure (supine to standing after 2 minutes). Screen for recurrent urinary tract infections, perineal skin breakdown, or prior genital mycotic infections. Review the full medication list for concurrent diuretics, NSAIDs, ACE inhibitors, and ARBs. Assess frailty using the CFS or Fried Phenotype. Confirm HbA1c if prescribing for a glucose-lowering indication.

2 to 4 Weeks Post-Initiation

Recheck eGFR and potassium. An initial eGFR dip of 5 to 10 mL/min/1.73m² is expected and does not warrant discontinuation unless accompanied by symptoms of acute kidney injury or a drop exceeding 30% from baseline. Reassess orthostatic blood pressure. EMPA-KIDNEY investigators noted that initial eGFR decline stabilizes by week 4 in most patients and is followed by a slower rate of decline over years.

Ongoing Every 3 Months

Repeat eGFR, electrolytes, and blood pressure. For patients with HF, assess volume status clinically (jugular venous pressure, peripheral edema, weight). For patients with T2DM, check HbA1c every 6 months if targets are stable. Screen for genital symptoms at each visit, as older patients may not volunteer this information without direct questioning. A 2022 JAMA Geriatrics perspective noted that adverse-effect reporting rates for genital infections are lower in older adults partly due to patient reluctance to disclose, underscoring the need for proactive inquiry.

Prescribing Empagliflozin in Nursing Home and Long-Term Care Settings

Adults residing in skilled nursing facilities or assisted living represent the highest-frailty segment of the geriatric population. Polypharmacy, inconsistent oral intake, and limited nursing monitoring capacity raise the risk profile for empagliflozin significantly.

A 2021 analysis in JAMDA (Journal of the American Medical Directors Association) examined SGLT2 inhibitor use in nursing home residents with T2DM and found a 2.3-fold higher rate of urinary tract infection-related hospitalizations in SGLT2 inhibitor users versus comparators receiving DPP-4 inhibitors. Urinary frequency from osmotic diuresis may also worsen incontinence, reducing quality of life and increasing fall risk in residents already requiring assistance with toileting.

For residents with eGFR above 30 mL/min/1.73m² and established HF or CKD, the cardiovascular and renal benefits documented in EMPA-KIDNEY and EMPEROR-Preserved may still justify use, but the decision should involve the patient, family or proxy, and care team. Empagliflozin should be held during any acute illness associated with reduced oral intake, fever, or diarrhea, per FDA label guidance, and resumed only after clinical stability returns.